Work to close gap between clinical care and clinical research to improve patient lives, decrease costs and improve efficiency
Coordinate strategy between stakeholders and leverage existing work within HL7 and other groups including FDA, HL7, NCATS, NLM, Danish Medicines Agency, SCDM, TransCelerate Bio Pharma, and others
Leverage shared community and resources to be able to communicate the return on investment and return on value that a unified network could realize to various parties, and provide comprehensive recommendations to global regulators
Develop necessary FHIR Research Resources to maturity. Accelerator program will handle identified and prioritized use cases for secondary use of EHR data that meet interested parties needs and goals
Sign up to receive updates, news, and more.